دورية أكاديمية
Izervay versus Syfovre: Two Rivals Recently Approved for Management of Geographic Atrophy.
| العنوان: | Izervay versus Syfovre: Two Rivals Recently Approved for Management of Geographic Atrophy. |
|---|---|
| المؤلفون: | Patel H; Department of General Medicine, Gmers Sola Medical College and Hospital, Ahmedabad, Gujarat, India., Kutikuppala LVS; Department of Pharmacology, All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh, India., Sharma S; Department of Pharmacology, All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh, India., Chavan M; Department of Pharmacology, All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh, India., Rangari G; Department of Pharmacology, All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh, India., Misra AK; Department of Pharmacology, All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh, India., Rao KS; Department of Pharmacology, All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh, India. |
| المصدر: | Annals of African medicine [Ann Afr Med] 2024 Jul 01; Vol. 23 (3), pp. 523-524. Date of Electronic Publication: 2024 Jul 20. |
| نوع المنشور: | Letter; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Medknow Publications Country of Publication: India NLM ID: 101231417 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 0975-5764 (Electronic) Linking ISSN: 09755764 NLM ISO Abbreviation: Ann Afr Med Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Mumbai, India : Medknow Publications Original Publication: Sokoto, Nigeria : [Zaria, Nigeria?] : Usmanu Danfodiyo University Teaching Hospital ; Annals of African Medicine Society |
| مواضيع طبية MeSH: | Geographic Atrophy*/drug therapy, Humans ; Treatment Outcome |
| References: | Holm DL, Nielsen MK, Højsted BB, Sørensen TL. Vision-related quality of life is selectively affected by comorbidities in patients with geographic atrophy. BMC Ophthalmol 2023;23:153. Catherine E. FDA approves first treatment for geographic atrophy. European Pharmaceutical Review; 2023. Available from: https://www.europeanpharmaceuticalreview.com/news/179738/fda-approves-first-treatment-for-geographic-atrophy/ . [Last accessed on 2023 Aug 16]. Arshad MK. FDA approves Izervay to treat geographic atrophy. Formulary Watch; 2023. Available from: https://www.formularywatch.com/view/fda-approves-izervay-to-treat-geographic-atrophy . [Last accessed on 2023 Aug 16]. Joszt L. Effects of pegcetacoplan to slow progression of GA increase over time: Dr. Eleonora Lad. Am J Manag Care; 2023. Available from: https://www.ajmc.com/view/effects-of-pegcetacoplan-to-slow-progression-of-ga-increase-over-time-dr-eleonora-lad . [Last accessed on 2023 Aug 18]. Fidler B. Iveric drug approved for type of vision loss as rival’s safety draws scrutiny. BioPharma Dive; 2023. Available from: https://www.biopharmadive.com/news/astellas-iveric-fda-approval-geographic-atrophy-izervay/690052/ . [Last accessed on 2023 Aug 19]. |
| تواريخ الأحداث: | Date Created: 20240722 Date Completed: 20240722 Latest Revision: 20240722 |
| رمز التحديث: | 20240722 |
| DOI: | 10.4103/aam.aam_186_23 |
| PMID: | 39034586 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 0975-5764 |
|---|---|
| DOI: | 10.4103/aam.aam_186_23 |